Skip to main content

Table 2 Ongoing trials investigating the combination therapy of TKIs and ICIs

From: Emerging treatment modalities for systemic therapy in hepatocellular carcinoma

Targeted therapy Checkpoint inhibitor Phase Patients No. Clinical setting Status NCT numbers
Lenvatinib Nivolumab I 30 HCC without prior systemic therapy Active, not recruiting NCT03418922
Lenvatinib Nivolumab II 50 Multinodular, advanced HCC Recruiting NCT03841201
Lenvatinib Pembrolizumab I 104 HCC Active, not recruiting NCT03006926
Lenvatinib Pembrolizumab III 750 Advanced HCC Active, not recruiting NCT03713593
Regorafenib Nivolumab I/II 60 HCC progressing under sorafenib Recruiting NCT04170556
Regorafenib Nivolumab II 42 Unresectable HCC Recruiting NCT04310709
Regorafenib Nivolumab III 496 Intermediate-Stage HCC Not yet recruiting NCT04777851
Regorafenib Pembrolizumab I 57 Advanced liver cancer without prior systemic therapy Active, not recruiting NCT03347292
Regorafenib Pembrolizumab II 119 Advanced or metastatic HCC after ICIs Recruiting NCT04696055
Cabozantinib Nivolumab I 15 Locally advanced HCC after definitive resection Active, not recruiting NCT03299946
Cabozantinib Nivolumab I 18 Advanced Solid Tumors in Patients with HIV Infection Recruiting NCT04514484
Cabozantinib Pembrolizumab II 29 Liver cancer not eligible for local therapy Recruiting NCT04442581
Sorafenib/lenvatinib Atezolizumab III 554 Locally advanced or metastatic and/or unresectable HCC participants following prior HCC treatment with atezolizumab and bevacizumab combination Not yet recruiting NCT04770896
Bevacizumab Nivolumab II 60 Advanced HCC Recruiting NCT04393220
Bevacizumab Atezolizumab III 662 HCC with high risk of recurrence after surgical resection or ablation Recruiting NCT04102098
Bevacizumab Atezolizumab III 150 Unresectable HCC without prior systemic treatment Recruiting NCT04487067
Bevacizumab Atezolizumab III 480 Locally advanced or metastatic HCC without prior systemic treatment Completed NCT03434379